Clinical Focus

  • Neurological Surgery

Academic Appointments

Professional Education

  • Fellowship: NHS Grampian Aberdeen Royal Infirmary (2023) United Kingdom
  • Fellowship: North Bristol NHS Trust (2023) United Kingdom
  • Board Certification: General Medical Council, Neurological Surgery (2016)
  • Residency: NHS Lothian Western General Hospital (2016) United Kingdom
  • Residency: Southern General Hospital (Closed) (2005) United Kingdom
  • Internship: Western General Hospital (Closed 2015) (1999) United Kingdom
  • Medical Education: University of Aberdeen (1998) Scotland

Contact

  • Clinical (Primary)  Stanford Neuroscience Health Center 213 Quarry Rd MC 5957 Fl 2 Palo Alto, CA 94304 (650) 725-0390 (fax)

Additional Clinical Info

All Publications

  • Targeted multinodal thalamic deep brain stimulation for epilepsy: A retrospective case series. Epileptic disorders : international epilepsy journal with videotape Chang, R., Reid, B., McGeoch, P., Lusk, Z., Graber, K., Fisher, R., Parvizi, J., Buch, V. 2025

    Abstract

    Emerging literature suggests that multi-lead thalamic DBS may be safe and therapeutically beneficial to patients with diffuse or poorly defined epileptic networks; however, more studies are needed to support such off-label methods. Here, in a single-center retrospective, non-controlled observational pilot study, we investigated the off-label use of a multinodal thalamic DBS system in patients with medically refractory and poorly localized epilepsies.Utilizing either a robotic or frame-based technique, we implanted four DBS leads (Boston Scientific, Marlborough, MA) into either bilateral (1) ANT and CM (n = 6 patients) or (2) ANT and PLV (n = 4 patients). In five patients, only bilateral ANT (n = 2) or CM (n = 3) stimulations were applied while in five other patients, bilateral ANT was supplemented with bilateral CM (n = 1) or PLV (n = 4) DBS. The thalamic targets were personalized in each patient based on available clinical or intracranial multi-site thalamic stereoencephalography or scalp EEG evidence. Primary outcomes were intraoperative and postoperative complications as well as changes in seizure frequency.DBS implantation was well tolerated with no intraoperative complications. Only one patient had a post-operative wound-related complication. Average follow-up was 12.4 months (range 3-21 months). Most patients (nine out of 10 patients) experienced a clinically noticeable reduction in seizure frequency, including a subset (two out of 10 patients) who were seizure free. Efficacy was similar in the two-lead and four-lead stimulation groups.This cohort provides early and preliminary data documenting the feasibility and safety (and clinical utility) of targeted multinodal thalamic DBS for medically refractory, poorly localized epilepsy. As this was not a controlled outcomes study, the clinical efficacy data must be interpreted cautiously. Our findings may motivate larger controlled studies to rigorously evaluate the clinical efficacy of personalized optimization of multinodal configuration in patients with diffuse or poorly defined epileptic networks.

    View details for DOI 10.1002/epd2.70070

    View details for PubMedID 40699906

  • Vestibular nerve stimulation may treat post-traumatic stress disorder MEDICAL HYPOTHESES McKeown, J., McGeoch, P. D. 2025; 199

    View details for DOI 10.1016/j.mehy.2025.111650

    View details for Web of Science ID 001492582100001

  • Non-invasive vestibular nerve stimulation (VeNS) reduces visceral adipose tissue: results of a randomised controlled trial. Scientific reports Viirre, E., Sittlington, J., Wing, D., Price, R., Logue, C., Moreno, D., Ledford-Mills, J., Knott, C., le Roux, C. W., Grieve, D., Watson, S., McKeown, J., McGeoch, P. D. 2025; 15 (1): 8753

    Abstract

    Across multiple species, chronic vestibular stimulation activates hypothalamic regions involved in energy homeostasis and reduces body fat. This first-in-human randomised controlled trial evaluated the efficacy and safety of electrical vestibular nerve stimulation (VeNS) as a means of reducing excess body weight and fat. Overweight and obese adults were randomised 1:1 to receive 60min of daily VeNS (n=117) or sham stimulation (n=124) for 6months, together with a hypocaloric diet. The primary endpoints were weight loss based. Secondary endpoints included reduction in visceral adipose tissue (VAT). It is VAT, more than subcutaneous fat depots, which is particularly associated with the risks associated with obesity. The weight loss based primary endpoints were not met. However, mean change in VAT was significantly greater in the active (-12.6%) versus the sham (-4.7%) group (p=0.03). This suggests that regular VeNS may cause a clinically meaningful reduction in VAT.

    View details for DOI 10.1038/s41598-025-92744-9

    View details for PubMedID 40082596